4568.T
DAIICHI SANKYO COMPANY,LIMITED
プライム · 医薬品 · 医薬品 · JP
JPY 2,854.50
−0.99%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2123.0B | 2123.0B | 1886.3B | 1601.7B | 1278.5B |
| Cost of Revenue | 92.3B | 669.0B | 415.8B | 415.3B | 363.5B |
| Gross Profit | 382.3B | 1454.0B | 1470.5B | 1186.4B | 915.0B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 180.3B | 780.7B | 731.2B | 637.0B | 471.2B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 323.0M | 107.0M | 88.0M | 680.0M |
| Total Operating Expenses | 180.3B | 781.0B | 731.3B | 637.1B | 471.9B |
| Cost and Expenses | 1894.0B | 1894.0B | 1554.3B | 1390.1B | 1157.9B |
| Operating Income (EBIT) | 229.1B | 229.1B | 331.9B | 211.6B | 120.6B |
| Non-Operating | |||||
| Interest Income | 9.8B | 40.8B | 34.1B | 31.5B | 14.8B |
| Interest Expense | 1.4B | 8.0B | 11.9B | 6.0B | 8.5B |
| Net Interest Income | 8.4B | 32.8B | 22.2B | 25.5B | 6.3B |
| Other Non-Op Income/Expense | 760.0M | 22.1B | 28.7B | 27.5B | 19.1B |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 105.4B | 263.4B | 355.6B | 237.2B | 126.9B |
| Income Tax Expense | 19.9B | 3.6B | 59.9B | 36.2B | 17.7B |
| Bottom Line | |||||
| Net Income | 259.9B | 259.9B | 295.8B | 200.7B | 109.2B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 259.9B | 259.9B | 295.8B | 201.0B | 109.2B |
| Per Share | |||||
| Basic EPS | ¥140 | ¥140 | ¥156 | ¥105 | ¥57 |
| Diluted EPS | ¥140 | ¥140 | ¥156 | ¥105 | ¥57 |
| Revenue Per Share | ¥1,147 | ¥1,147 | ¥995 | ¥835 | ¥667 |
| Shares | |||||
| Basic Shares Outstanding | 1.9B | 1.9B | 1.9B | 1.9B | 1.9B |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 114.5B | 306.5B | 400.6B | 271.2B | 188.4B |
| D&A | 17.8B | 77.5B | 68.6B | 59.6B | 67.8B |
| EBIT | 229.1B | 229.1B | 331.9B | 211.6B | 120.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026